ES2542059T3 - Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones - Google Patents
Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones Download PDFInfo
- Publication number
- ES2542059T3 ES2542059T3 ES08786050.8T ES08786050T ES2542059T3 ES 2542059 T3 ES2542059 T3 ES 2542059T3 ES 08786050 T ES08786050 T ES 08786050T ES 2542059 T3 ES2542059 T3 ES 2542059T3
- Authority
- ES
- Spain
- Prior art keywords
- hgf
- cells
- cdr
- met
- significant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000006471 dimerization reaction Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 239000000556 agonist Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241001421711 Mithras Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015916 branching morphogenesis of a tube Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92978907P | 2007-07-12 | 2007-07-12 | |
| US929789P | 2007-07-12 | ||
| EP07301231 | 2007-07-12 | ||
| EP07301231A EP2014681A1 (en) | 2007-07-12 | 2007-07-12 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US2063908P | 2008-01-11 | 2008-01-11 | |
| US20639P | 2008-01-11 | ||
| PCT/EP2008/059026 WO2009007427A2 (en) | 2007-07-12 | 2008-07-10 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2542059T3 true ES2542059T3 (es) | 2015-07-30 |
Family
ID=38871713
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08786050.8T Active ES2542059T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES12183761.1T Active ES2686693T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES11162718.8T Active ES2686335T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES11162720.4T Active ES2678495T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES12183763.7T Active ES2693542T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12183761.1T Active ES2686693T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES11162718.8T Active ES2686335T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES11162720.4T Active ES2678495T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
| ES12183763.7T Active ES2693542T3 (es) | 2007-07-12 | 2008-07-10 | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones |
Country Status (35)
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2143441A1 (en) | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US20140112911A9 (en) * | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| CN102361883A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
| PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR101671378B1 (ko) | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| KR101748707B1 (ko) | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
| JP6055312B2 (ja) * | 2010-03-10 | 2017-01-11 | ゲンマブ エー／エス | Ｃ−ｍｅｔに対するモノクローナル抗体 |
| JP2013534515A (ja) * | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体 |
| EP2402370A1 (en) * | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| JP2013537966A (ja) | 2010-08-31 | 2013-10-07 | ジェネンテック， インコーポレイテッド | バイオマーカー及び治療の方法 |
| SG188324A1 (en) | 2010-09-03 | 2013-04-30 | Academia Sinica | Anti-c-met antibody and methods of use thereof |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US8637027B2 (en) | 2010-11-03 | 2014-01-28 | Argen-X B.V. | Anti c-Met antibodies |
| EP2643351A1 (en) | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| KR101444837B1 (ko) * | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| CN106046168A (zh) * | 2011-06-23 | 2016-10-26 | 埃博灵克斯股份有限公司 | 结合血清白蛋白的蛋白 |
| SG194982A1 (en) | 2011-06-23 | 2013-12-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2013003680A1 (en) * | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| HK1199883A1 (en) | 2011-08-26 | 2015-07-24 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| KR20140064971A (ko) | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| EP2758430A4 (en) | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
| JP6219287B2 (ja) * | 2011-09-30 | 2017-10-25 | アブリンクス エン．ヴェー． | ｃ−Ｍｅｔに関連する生物学的物質 |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| KR101865223B1 (ko) * | 2011-10-05 | 2018-06-08 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| WO2013064700A2 (en) | 2011-11-03 | 2013-05-10 | Argen-X B.V. | Chimeric polypeptides and methods of use |
| WO2013078170A1 (en) | 2011-11-21 | 2013-05-30 | Genentech, Inc. | Purification of anti-c-met antibodies |
| US20150147274A1 (en) | 2011-12-02 | 2015-05-28 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
| US8900582B2 (en) | 2011-12-22 | 2014-12-02 | Samsung Electronics Co., Ltd. | Deimmunized anti c-Met humanized antibodies and uses thereof |
| WO2013130565A1 (en) * | 2012-02-29 | 2013-09-06 | The Brigham And Women's Hosptial, Inc. | Neutralizing antibody for epstein barr virus associated disease |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP6429771B2 (ja) | 2012-06-21 | 2018-11-28 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ｃ−Ｍｅｔに結合する抗原結合タンパク質 |
| KR101938698B1 (ko) | 2012-07-23 | 2019-01-16 | 삼성전자주식회사 | Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도 |
| KR101938699B1 (ko) | 2012-07-23 | 2019-01-16 | 삼성전자주식회사 | Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도 |
| AU2013302441B2 (en) * | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Ｓｃｉｖａｘ株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
| EP2839860B1 (en) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| WO2014074907A1 (en) * | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| KR101911048B1 (ko) | 2013-01-29 | 2018-10-24 | 삼성전자주식회사 | ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물 |
| HK1211235A1 (en) | 2013-02-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| KR102139607B1 (ko) * | 2013-04-01 | 2020-07-30 | 삼성전자주식회사 | 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| WO2015031614A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015031626A1 (en) | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| US9717715B2 (en) | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
| CA2943329A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| CA2944717A1 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| AU2015316522B2 (en) | 2014-09-16 | 2021-01-21 | Symphogen A/S | Anti-met antibodies and compositions |
| EP3200825A4 (en) | 2014-10-03 | 2018-03-21 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| WO2016053610A1 (en) * | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| US11035860B2 (en) * | 2014-11-20 | 2021-06-15 | Stichting Katholieke Universiteit | Auto-active and intracellular mutant of MET |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| EP3233910B1 (en) | 2014-12-19 | 2019-12-11 | Ablynx N.V. | Cysteine linked nanobody dimers |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| CN107613974B (zh) * | 2015-03-16 | 2021-01-15 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| US10273305B2 (en) | 2015-04-02 | 2019-04-30 | Ablynx N.V. | Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity |
| TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| US20190194345A1 (en) * | 2015-10-05 | 2019-06-27 | University Of Virginia Patent Foundation | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer |
| JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
| WO2017173091A1 (en) * | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
| ES2864150T3 (es) | 2016-05-17 | 2021-10-13 | Abbvie Biotherapeutics Inc | Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso |
| BR112019000166A2 (pt) * | 2016-07-06 | 2019-10-01 | Celgene Corp | anticorpos com baixa imunogenicidade e usos dos mesmos |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RECOMBINANT ANTIBODIES BINDING TO CD123 |
| WO2019117691A1 (ko) * | 2017-12-15 | 2019-06-20 | 경북대학교 산학협력단 | CD44v6에 결합하는 펩타이드 및 이의 용도 |
| KR102194025B1 (ko) | 2017-12-15 | 2020-12-22 | 경북대학교 산학협력단 | CD44v6에 결합하는 펩타이드 및 이의 용도 |
| EP3772927B1 (en) * | 2018-03-24 | 2025-01-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| KR20210016562A (ko) | 2018-05-23 | 2021-02-16 | 에이디씨 테라퓨틱스 에스에이 | 분자 애쥬번트 |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN109541221B (zh) * | 2018-10-24 | 2022-03-22 | 益善生物技术股份有限公司 | 一种c-Met特异性抗体、组合物及试剂盒 |
| CN115605491A (zh) | 2019-04-05 | 2023-01-13 | 刘扶东（Us） | 抗唾液酸酶的糖类、其制造方法及用途 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| CA3182526A1 (en) | 2020-05-08 | 2021-11-11 | Academia Sinica | Chimeric influenza vaccines |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| WO2022126416A1 (zh) * | 2020-12-16 | 2022-06-23 | 武汉友芝友生物制药股份有限公司 | 抗bcma抗体及其制备方法和应用 |
| CN112679614B (zh) * | 2021-01-15 | 2022-08-16 | 广东安普泽生物医药股份有限公司 | 用于特异性结合rankl靶向治疗药物的抗体及其用途 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN112946279A (zh) * | 2021-03-17 | 2021-06-11 | 扬州大学 | 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法 |
| MX2023011733A (es) | 2021-04-06 | 2023-10-13 | Abbvie Biotherapeutics Inc | Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin. |
| BR112023000666A2 (pt) | 2021-04-12 | 2023-10-24 | Academia Sinica | Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica |
| TWI895608B (zh) | 2021-04-29 | 2025-09-01 | 愛爾蘭商艾伯維製造管理無限公司 | 抗c-Met抗體藥物結合物 |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| JP2024541058A (ja) | 2021-11-03 | 2024-11-06 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 抗体の特異的共役 |
| EP4457243A4 (en) * | 2021-12-27 | 2025-12-17 | Academia Sinica | ANTIBODIES AGAINST THE SPIKE PROTEIN OF SARS-CoV-2 AND USES THEREOF |
| WO2024131846A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| US12318485B2 (en) | 2023-04-08 | 2025-06-03 | Rock Biomedical, Inc. | Methods and compositions for targeted delivery by polymersomes |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2840250C2 (de) | 1978-09-15 | 1983-01-20 | Siemens AG, 1000 Berlin und 8000 München | Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US7227002B1 (en) * | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1476120B1 (en) * | 2002-02-21 | 2010-09-29 | Duke University | Treatment methods using anti-cd22 antibodies |
| WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| JP5416338B2 (ja) * | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Ｃｄ２０特異的抗体およびその使用方法 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| WO2005058965A1 (en) * | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| PT1773885E (pt) * | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
| US20060094059A1 (en) | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
| AU2006213800B2 (en) * | 2005-02-10 | 2012-02-09 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| CA2854576A1 (en) | 2005-07-18 | 2007-01-25 | Haichun Huang | Human anti-b7rp1 neutralizing antibodies |
| US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
| BRPI0707480A8 (pt) | 2006-02-06 | 2022-11-08 | Vertical Bio Ag | Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos |
| JP5536445B2 (ja) | 2006-03-30 | 2014-07-02 | ノバルティス アーゲー | ｃ−Ｍｅｔの抗体の組成物およびその使用方法 |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
-
2007
- 2007-07-12 EP EP07301231A patent/EP2014681A1/en not_active Withdrawn
-
2008
- 2008-07-10 DK DK08786050.8T patent/DK2188312T3/en active
- 2008-07-10 PA PA20088789201A patent/PA8789201A1/es unknown
- 2008-07-10 HR HRP20150887TT patent/HRP20150887T1/hr unknown
- 2008-07-10 NZ NZ599959A patent/NZ599959A/xx unknown
- 2008-07-10 CA CA2981821A patent/CA2981821C/en active Active
- 2008-07-10 ES ES08786050.8T patent/ES2542059T3/es active Active
- 2008-07-10 ES ES12183761.1T patent/ES2686693T3/es active Active
- 2008-07-10 RU RU2010104633/10A patent/RU2552161C2/ru active
- 2008-07-10 AU AU2008274171A patent/AU2008274171B2/en active Active
- 2008-07-10 BR BRPI0815564A patent/BRPI0815564B8/pt active IP Right Grant
- 2008-07-10 ES ES11162718.8T patent/ES2686335T3/es active Active
- 2008-07-10 CL CL2008002015A patent/CL2008002015A1/es unknown
- 2008-07-10 ES ES11162720.4T patent/ES2678495T3/es active Active
- 2008-07-10 MX MX2014007693A patent/MX353449B/es unknown
- 2008-07-10 PT PT87860508T patent/PT2188312E/pt unknown
- 2008-07-10 EP EP08786050.8A patent/EP2188312B1/en active Active
- 2008-07-10 EP EP12183763.7A patent/EP2535357B1/en active Active
- 2008-07-10 KR KR1020167002899A patent/KR101701686B1/ko active Active
- 2008-07-10 WO PCT/EP2008/059026 patent/WO2009007427A2/en not_active Ceased
- 2008-07-10 NZ NZ599958A patent/NZ599958A/xx not_active IP Right Cessation
- 2008-07-10 SI SI200831467T patent/SI2188312T1/sl unknown
- 2008-07-10 CN CN200880024368.4A patent/CN101981054B/zh active Active
- 2008-07-10 KR KR1020107003216A patent/KR101625234B1/ko active Active
- 2008-07-10 HU HUE08786050A patent/HUE026026T2/en unknown
- 2008-07-10 CN CN201310478511.XA patent/CN103509112B/zh active Active
- 2008-07-10 EP EP11162718.8A patent/EP2415784B1/en active Active
- 2008-07-10 MY MYPI2010000127A patent/MY158756A/en unknown
- 2008-07-10 CA CA2888691A patent/CA2888691C/en active Active
- 2008-07-10 US US12/440,571 patent/US8329173B2/en active Active
- 2008-07-10 PL PL08786050T patent/PL2188312T3/pl unknown
- 2008-07-10 EP EP12183761.1A patent/EP2535356B1/en active Active
- 2008-07-10 JP JP2010515513A patent/JP5562844B2/ja active Active
- 2008-07-10 EP EP11162720.4A patent/EP2415785B1/en active Active
- 2008-07-10 KR KR1020167002898A patent/KR101701685B1/ko active Active
- 2008-07-10 SG SG2012050837A patent/SG183015A1/en unknown
- 2008-07-10 NZ NZ583041A patent/NZ583041A/en unknown
- 2008-07-10 MX MX2014008274A patent/MX345391B/es unknown
- 2008-07-10 CN CN201310478556.7A patent/CN103509113B/zh active Active
- 2008-07-10 KR KR1020157015922A patent/KR101719084B1/ko active Active
- 2008-07-10 NZ NZ613716A patent/NZ613716A/en not_active IP Right Cessation
- 2008-07-10 ES ES12183763.7T patent/ES2693542T3/es active Active
- 2008-07-10 CA CA2694418A patent/CA2694418C/en active Active
- 2008-07-10 CN CN201310073997.9A patent/CN103183739B/zh active Active
- 2008-07-10 ME MEP-2016-197A patent/ME02341B/me unknown
- 2008-07-10 CA CA2982484A patent/CA2982484C/en active Active
- 2008-07-10 RS RS20150560A patent/RS54197B1/sr unknown
- 2008-07-11 TW TW103121603A patent/TWI592427B/zh active
- 2008-07-11 TW TW097126356A patent/TWI549965B/zh active
- 2008-07-11 TW TW104114444A patent/TWI602829B/zh active
- 2008-07-11 AR ARP080102991A patent/AR067517A1/es active IP Right Grant
- 2008-07-11 TW TW104114445A patent/TWI602830B/zh active
- 2008-07-12 SA SA08290423A patent/SA08290423B1/ar unknown
-
2010
- 2010-01-03 IL IL203114A patent/IL203114A/en active IP Right Grant
- 2010-01-08 TN TNP2010000016A patent/TN2010000016A1/fr unknown
- 2010-01-08 MX MX2013010752A patent/MX341012B/es unknown
- 2010-02-10 MA MA32608A patent/MA31977B1/fr unknown
- 2010-02-10 ZA ZA2010/00966A patent/ZA201000966B/en unknown
- 2010-02-12 CO CO10016035A patent/CO6170364A2/es active IP Right Grant
-
2012
- 2012-11-09 US US13/673,716 patent/US8871910B2/en active Active
- 2012-11-09 US US13/673,752 patent/US9107907B2/en active Active
- 2012-11-09 US US13/673,726 patent/US8889832B2/en active Active
- 2012-11-09 US US13/673,690 patent/US8871909B2/en active Active
- 2012-11-18 IL IL223109A patent/IL223109B/en active IP Right Grant
- 2012-11-18 IL IL223106A patent/IL223106B/en active IP Right Grant
- 2012-11-18 IL IL223105A patent/IL223105B/en active IP Right Grant
- 2012-11-18 IL IL223108A patent/IL223108B/en active IP Right Grant
-
2014
- 2014-01-06 JP JP2014000618A patent/JP5889925B2/ja active Active
- 2014-01-06 JP JP2014000616A patent/JP5889923B2/ja active Active
- 2014-01-06 JP JP2014000617A patent/JP5889924B2/ja active Active
-
2015
- 2015-03-17 US US14/660,046 patent/US20150252114A1/en not_active Abandoned
- 2015-08-04 CY CY20151100680T patent/CY1116608T1/el unknown
-
2017
- 2017-09-15 AR ARP170102558A patent/AR109659A2/es unknown
- 2017-09-15 AR ARP170102559A patent/AR109660A2/es unknown
- 2017-09-15 AR ARP170102560A patent/AR109535A2/es unknown
-
2018
- 2018-09-24 PH PH12018502038A patent/PH12018502038A1/en unknown
- 2018-09-24 PH PH12018502039A patent/PH12018502039A1/en unknown
- 2018-09-24 PH PH12018502040A patent/PH12018502040A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2542059T3 (es) | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones | |
| Chu et al. | Transforming growth factor-β2 induces bronchial epithelial mucin expression in asthma | |
| Zhang et al. | Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis | |
| Frasca et al. | Aging affects human B cell responses | |
| Antoniades et al. | Secretory leukocyte protease inhibitor: a pivotal mediator of anti‐inflammatory responses in acetaminophen‐induced acute liver failure | |
| Ohbayashi et al. | Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis | |
| Deng et al. | Leptin exacerbates collagen‐induced arthritis via enhancement of Th17 cell response | |
| Koslow et al. | ROCK inhibitor increases proacinar cells in adult salivary gland organoids | |
| Carito et al. | Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth | |
| Lu et al. | Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer | |
| AR108779A1 (es) | Anticuerpos | |
| AR066170A1 (es) | Anti integrina alfa 5 beta 1 | |
| Fu et al. | Intestinal CD11b+ B cells ameliorate colitis by secreting immunoglobulin A | |
| Mirzamani et al. | Increased expression of transforming growth factor-β and receptors in primary human airway fibroblasts from chemical inhalation patients | |
| Laberge et al. | Shedding of proangiogenic microvesicles from hypertrophic scar myofibroblasts | |
| Jones et al. | Bone marrow-derived stem cells and respiratory disease | |
| AR089028A1 (es) | Composiciones y metodos para el analisis de cancer de prostata | |
| Tang et al. | Wip1 knockout inhibits the proliferation and enhances the migration of bone marrow mesenchymal stem cells | |
| Faith et al. | Functional plasticity of human respiratory tract dendritic cells: GM-CSF enhances TH2 development | |
| Wang et al. | M2 macrophages promote subconjunctival fibrosis through YAP/TAZ signalling | |
| Michalik et al. | Transition of asthmatic bronchial fibroblasts to myofibroblasts is inhibited by cell–cell contacts | |
| JP2016517439A (ja) | 医学的状態の治療のためのクロマチン修飾因子の標的化 | |
| Hostettler et al. | Airway epithelium‐derived transforming growth factor‐β is a regulator of fibroblast proliferation in both fibrotic and normal subjects | |
| Cong et al. | Retracted: Upregulation of Klotho potentially inhibits pulmonary vascular remodeling by blocking the activation of the Wnt signaling pathway in rats with PM2. 5‐induced pulmonary arterial hypertension | |
| BR112018016142A2 (pt) | combinações de dicloridrato de histamina e seus usos |